The new dosing schedule with a more gradual titration significantly lowered incidence of ARIA-E in the TRAILBLAZER-ALZ 6 trial.

A new weekly injectable drug could transform the lives of more than eight million people living with Parkinson's disease, ...

The letters, many of which were already available online, detail why the regulators initially declined to approve some drugs.

The FDA has updated the labeling for Kisunla™ (donanemab-azbt) to include a new recommended titration dosing schedule for adults with early symptomatic Alzheimer disease.